# Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

> **NCT04126317** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 106 (actual)

## Conditions studied

- Neovascular (Wet) Age-Related Macular Degeneration

## Interventions

- **DRUG:** aflibercept
- **DRUG:** High-dose aflibercept

## Key facts

- **NCT ID:** NCT04126317
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-04
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-11-30
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126317, "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04126317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*